Why the study?
What are the pharmacokinetic properties of eprosartan in healthy subjects and special populations?
Population
Healthy subjects, patients with hypertension, and special populations
Design
Review
Authors
Loading...
Supports no initial adjustment in special populations despite higher exposure; extends PK review data but leaves open prospective confirmation.
What are the pharmacokinetic properties of eprosartan in healthy subjects and special populations?
Eprosartan has a predictable pharmacokinetic profile and can be safely administered without initial dosage adjustment in the elderly or patients with renal or hepatic impairment.
Bottorff et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: